Teva Pharmaceutical Industries Limited (TEVA)

NYSE - NYSE Real Time Price. Currency in USD
At close: 4:02 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close53.48
Bid53.17 x 100
Ask53.30 x 200
Day's Range53.11 - 53.83
52wk Range48.01 - 66.55
1y Target EstN/A
Market Cap48.62B
P/E Ratio (ttm)35.54
Avg Vol (3m)5,464,343
Dividend & Yield1.36 (2.54%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Tiger Management Welcomes Microsoft, Pandora to Portfolio, Chases Off Netflix, Teva
    Insider Monkey14 hours ago

    Tiger Management Welcomes Microsoft, Pandora to Portfolio, Chases Off Netflix, Teva

    Tiger Management was founded in 1980 by billionaire and legendary investor Julian Robertson, who later closed the fund to outside investors and now manages his own money, as well as having provided seed capital for many successful hedge funds managed by former employees of his firm, known as ‘Tiger Cubs’. Mr. Robertson has a total net […]

  • Market Realist17 hours ago

    Will Anda Acquisition Improve Access to Teva’s Generic Drugs?

    On August 3, 2016, Teva Pharmaceutical (TEVA) announced that it will acquire Anda, Allergan’s pharmaceutical distributor business, for about $500 million.

  • Barrons.com18 hours ago

    Mylan: In EpiPen Controversy, Shades of Valeant

    If we learned anything from Valeant Pharmaceuticals International (VRX)--besides the fact that using a captive pharmacy to get around insurance companies is a really bad idea--it's that raising drug prices creates a lot of bad press and invites a ton of scrutiny. While the controversy probably won't hurt Mylan's earnings, it could have an impact on the price investors are willing to pay for the stock. Citigroup's Liav Abraham and Eugene Kim explain: The increased public scrutiny on EpiPen pricing that has been voiced both in the press as well as by politicians (on both sides of the political aisle) over the past few days could continue over the near term, we believe, as politicians continue to highlight drug pricing as an issue ahead of the upcoming election cycle, and consequently place pressure on the stock.